John Hancock becomes the first life insurance carrier to offer access to GRAIL''s multi-cancer early detection test to customers Highlights power of strategic industry partnerships to promote preventive health and empower well-being BOSTON , Sept. 20, 2022 |PRNewswire| -- Today, John Hancock , the US division of Toronto -based Manulife (NYSE: MFC ), announced it is offering access to GRAIL''s Galleri ® multi-cancer early detection test to a pilot group of existing customers through the John Hancock Vitality Program, in collaboration with reinsurer Munich Re Life US. As the first life insurance carrier to make this breakthrough screening technology available, John Hancock is enabling eligible customers to take proactive steps to better understand and make more informed choices about their health. According to the American Cancer Society, more than 600,000 people die from cancer each year in the United States and many cancers show no symptoms until later stages, when treatment options may be limited. 1 Early detection of cancer can improve cancer outcomes, yet today, many cancers are detected in late stages because only five types have recommended screenings — breast, cervical, colon, lung, and prostate cancers.